CureVac starts Phase IIb trial of CV9104

A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC).

According to a media release issued by the company, CureVac has initiated a randomized, double-blind Phase IIb trial of its investigational immunotherapeutic agent CV9104. The trial is designed to enroll up to 200 patients in eight different European countries between now and November this year. Eligible patients will have to be chemotherapy naive and have asymptomatic or minimally symptomatic mCRPC. The study’s primary endpoint is overall survival.

Details about this trial can be found on the web site.

The mechanism of action of CV9104 is based on CureVac’s proprietary RNActive® technology.

In September last year we had noted that CureVac was moving a slightly different product (CV9103) into Phase IIb trials as well.

2 Responses

  1. We need a drug that specifically attacks the prostate cancer cell. Eliminating testosterone is of limited benefit and associated with too many side effects. Increasing the immune response is also of limited benefit. Research must be directed to killing the the cancer cell.

  2. Dear Frank:

    Researchers have been trying to do this for the best part of 75 years. As yet, success has been very limited, although we do seem to have managed to do this for most forms of testicular cancer, which is one of very few forms of solid tumor that is actually curable through the use of drug therapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: